Prostate Cancer News
Top Stories
Radiation Therapy Prolongs Life in Men With Recurrent Prostate Cancer
POSTED: June 17, 2008BALTIMORE -- Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a "look-back" study of 635 men by Johns...
Diet Can Shut Off Cancer Genes
POSTED: June 17, 2008The benefits of eating right and staying active may extend well beyond your physique, all the way down to your genes, Bay Area scientists have found. Men with low-risk prostate cancer were able to change the activity of genes that affect tumor growth with diet and exercise, which could potentially reduce the risk of the cancer progressing. "So oft...
Blocking Signaling Protein Prevents Prostate Cancer Spread, Jefferson Scientists Find
POSTED: June 17, 2008Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay. In a series of experiments in bot...
Blocking Signaling Protein Prevents Prostate Cancer Spread, Jefferson Scientists Find
POSTED: June 13, 2008Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay. In a series of experiments in bot...
Bavarian Nordic Enters Clinical Trials With Prostate Cancer Vaccine
POSTED: June 13, 2008Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial...
The French Association Of Urology Defines The Indications For HIFU As Standard Of Care For Prostate Cancer
POSTED: June 13, 2008LYON, France -- EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that the British Journal of Urology (May 2008) published a systemic and comprehensive literature review of the outcomes of high intensity focused ultrasound (HIFU) as a treatment for prostate cancer. The purpose of this review, which was conducted by The Fr...
Poniard Announces Positive First-line Efficacy And Safety Data From Ongoing Phase 2 Trial Of Picoplatin In Patients With Metastatic Hormone Refractory Prostate Cancer
POSTED: June 13, 2008Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC). Results demonst...
Leading Academic Institutions Collaborate On 800-patient Study Of Effectiveness Of Cryoablation For Men With Recurrent Prostate Cancer
POSTED: June 13, 2008Endocare, Inc., an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation, announced that a group of the nation's leading academic institutions are collaborating on an 800-patient, multi-center, prospective study of the effectiveness of cryoablation on men whose prostate cancer has recurred after radiat...
Certain Form Of Tomatoes Could Be Key To Prostate Cancer Prevention
POSTED: June 13, 2008New cancer research from the University of Missouri suggests that eating a certain form of tomato product could be the key to unlocking the prostate cancer-fighting potential of the tomato. The positive effect of tomato products has been suggested in many studies, but, until now, researchers did not know exactly what caused this effect. "It appears t...
Report Identifies SPINK1 as a New Biomarker for Prostate Cancer
POSTED: June 10, 2008ANN ARBOR, Mich. -- Compendia Bioscience, Inc., the leading provider of cancer profiling data and analysis tools, today announced the central role of their flagship product Oncomine(TM) in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer. Oncomine is a rapidly growing compendium of n...
